Ohr Pharmaceuticals, Inc. (NASDAQ:OHRP) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.
According to Zacks, “Ohr Pharmaceutical, Inc. is a pharmaceutical company. It is focused on the development of novel therapeutics for the treatment of cancer cachexia, wet form of age-related macular degeneration and ophthalmic neovascularization disorders. Ohr Pharmaceutical, Inc. is headquartered in New York. “
Separately, HC Wainwright set a $10.00 target price on Ohr Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 16th.
Shares of Ohr Pharmaceuticals (OHRP) opened at 0.6489 on Thursday. Ohr Pharmaceuticals has a one year low of $0.56 and a one year high of $3.35. The stock’s market cap is $36.48 million. The company has a 50 day moving average price of $0.71 and a 200-day moving average price of $0.67.
Ohr Pharmaceuticals (NASDAQ:OHRP) last issued its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.18. Equities analysts predict that Ohr Pharmaceuticals will post ($0.95) earnings per share for the current fiscal year.
WARNING: This report was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.dispatchtribunal.com/2017/10/28/ohr-pharmaceuticals-inc-ohrp-rating-lowered-to-hold-at-zacks-investment-research.html.
A number of hedge funds have recently modified their holdings of OHRP. Cannell Peter B & Co. Inc. purchased a new stake in Ohr Pharmaceuticals during the 2nd quarter valued at about $187,000. Renaissance Technologies LLC boosted its holdings in Ohr Pharmaceuticals by 242.3% during the 1st quarter. Renaissance Technologies LLC now owns 229,709 shares of the biotechnology company’s stock valued at $191,000 after acquiring an additional 162,600 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in Ohr Pharmaceuticals by 0.7% during the 2nd quarter. Vanguard Group Inc. now owns 812,418 shares of the biotechnology company’s stock valued at $520,000 after acquiring an additional 5,481 shares during the period. Institutional investors own 7.03% of the company’s stock.
Ohr Pharmaceuticals Company Profile
OHR Pharmaceutical, Inc, a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.
Receive News & Ratings for Ohr Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.